HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats.

Abstract
Increased endothelin-1 may be associated with elevation of blood pressure (BP) and promotion of vascular hypertrophy, especially in salt-sensitive hypertension. Mineralocorticoid hypertension has been associated with activation of the endothelin system. We evaluated whether in aldosterone-infused rats the selective endothelin type A receptor-antagonist BMS 182874 prevents BP elevation and vascular hypertrophy. Rats were infused with aldosterone (0.75 microg/h) subcutaneously via a mini-osmotic pump and were offered 1% NaCl in the drinking water+/-BMS 182874 (40 mg/kg in food) for 6 weeks. Systolic BP was monitored by the tail-cuff method, and vascular changes of mesenteric arteries were evaluated using a pressurized myograph. Aldosterone-infusion significantly increased BP to 151+/-7 mm Hg compared with controls (108+/-4 mm Hg, P<0.01). BMS 182874 normalized BP (117+/-4 mm Hg). Media cross-sectional area of aorta was significantly increased by aldosterone infusion (P<0.05), and BMS treatment normalized it (P<0.001). Aldosterone infusion increased media width and media-to-lumen ratio of mesenteric resistance arteries (17.6+/-0.4 microm and 7.5+/-0.4%) compared with controls (14.2+/-0.5 microm, P<0.01, and 5.9+/-0.1%, P<0.05). BMS 182874 normalized media and media-to-lumen ratio (15.1+/-0.6 microm and 5.7+/-0.1%, both P<0.01). In conclusion, the endothelin type A receptor antagonist attenuated BP elevation and prevented vascular remodeling or hypertrophy of aorta and mesenteric resistance arteries in aldosterone-infused rats. These results suggest a role for endothelin-1 in BP elevation and structural alterations of large and small vessels in aldosterone and salt-induced hypertension.
AuthorsJ B Park, E L Schiffrin
JournalHypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 37 Issue 6 Pg. 1444-9 (Jun 2001) ISSN: 1524-4563 [Electronic] United States
PMID11408393 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Dansyl Compounds
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Endothelins
  • Protein Precursors
  • RNA, Messenger
  • Receptor, Endothelin A
  • 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide
  • Aldosterone
  • Potassium
Topics
  • Aldosterone (administration & dosage)
  • Animals
  • Antihypertensive Agents (therapeutic use)
  • Aorta (drug effects, metabolism, pathology)
  • Blood Pressure (drug effects)
  • Body Weight (drug effects)
  • Dansyl Compounds (therapeutic use)
  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Endothelins (biosynthesis, blood, genetics)
  • Hypertension (chemically induced, drug therapy, pathology, physiopathology)
  • Hypertrophy (chemically induced, drug therapy, pathology)
  • Infusions, Parenteral
  • Male
  • Mesenteric Arteries (drug effects, pathology, physiopathology)
  • Potassium (blood)
  • Protein Precursors (biosynthesis, genetics)
  • RNA, Messenger (biosynthesis)
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Endothelin A
  • Vasoconstriction (drug effects)
  • Vasodilation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: